Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs

International Journal of Rheumatic Diseases

Volumn 16, Issue 5, 2013, Pages 527-531

  Lee, Young Ho ^a   Bae, Sang Cheol ^b   Song, Gwan Gyu ^a  

^a Korea University College of Medicine   (South Korea)

^b Hanyang University Medical Center   (South Korea)

Author keywords

Anti tumor necrosis factor therapy; DMARD; Hepatitis B virus reactivation; Rheumatic diseases

Indexed keywords

ADALIMUMAB; ADEFOVIR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; ETANERCEPT; HEPATITIS B ANTIGEN; INFLIXIMAB; LAMIVUDINE; TUMOR NECROSIS FACTOR INHIBITOR; VIRUS DNA;

ANKYLOSING SPONDYLITIS; ARTICLE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS REACTIVATION;

ANTI-TUMOR NECROSIS FACTOR THERAPY; DMARD; HEPATITIS B VIRUS REACTIVATION; RHEUMATIC DISEASES;

ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; BIOLOGICAL PRODUCTS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; VIRUS ACTIVATION;

EID: 84886524794     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12154     Document Type: Article

References (23)

1. Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376, 1094-108.
2. Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21, 1366-71.
3. Ganem D, Prince AM (2004) Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 350, 1118-29.
4. Domm S, Cinatl J, Mrowietz U (2008) The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 159, 1217-28.
5. Tan J, Zhou J, Zhao P, Wei J (2012) Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 31, 1169-75.
6. Kim PS, Ho GY, Prete PE, Furst DE (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res 64, 1265-8.
7. Ryu HH, Lee EY, Shin K et al. (2012) Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases. Clin Rheumatol 31, 931-6.
8. Tamori A, Koike T, Goto H et al. (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46, 556-64.
9. Vassilopoulos D, Apostolopoulou A, Hadziyannis E et al. (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheumatic Dis 69, 1352-5.
10. Chung SJ, Kim JK, Park MC, Park YB, Lee SK (2009) Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36, 2416-20.
11. Li S, Kaur PP, Chan V, Berney S (2009) Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept, and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 28, 787-91.
12. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45, 1294-7.
13. Cho YT, Chen CH, Chiu HY, Tsai TF (2012) Use of anti-tumor necrosis factor-alpha therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: a case series in Taiwan. J Dermatol 39, 269-73.
14. Thong BY, Koh ET, Chng HH, Chow WC (2007) Outcomes of chronic hepatitis B infection in Oriental patients with rheumatic diseases. Ann Acad Med Singapore 36, 100-5.
15. Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS (2000) Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 18, 363-8.
16. Robinson H, Walker-Bone K (2009) Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology 48, 448-50.
17. Prignano F, Ricceri F, Pescitelli L, Zanieri F, Lotti T (2011) Tumour necrosis factor-alpha antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients. Br J Dermatol 164, 645-7.
18. Johnson DF, Leder K, Torresi J (2013) Hepatitis B and C infection in international travelers. J Travel Med 20, 194-202.
19. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F et al. (2011) Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine 90, 359-71.
20. Yeo W, Zee B, Zhong S et al. (2004) Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 90, 1306-11.
21. Schlaak JF, Tully G, Lohr HF, Gerken G, Meyer zum Buschenfelde KH (1999) HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 115, 508-14.
22. Saag KG, Teng GG, Patkar NM et al. (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59, 762-84.
23. Lee YH, Bae SC, Song GG (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol 31, 118-21.